NASDAQ$MRVI
Maravai LifeSciences Holdings Inc. · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Reported a record-setting first quarter with total revenues reaching $244.3 million, up 65% over the first quarter of 2021.
Maravai LifeSciences reported a strong first quarter in 2022, with record quarterly revenue of $244.3 million, representing a 65% increase over the prior year. Net income also saw significant growth, reaching $146.9 million, a 95% increase over the prior year. The company has affirmed its revenue guidance and raised its adjusted EBITDA and adjusted EPS guidance for the full year 2022.
- Record quarterly revenue of $244.3 million, an increase of 65% over the prior year.
- Nucleic Acid Production base business revenue (excluding COVID-19 related CleanCap® revenue) increased 55% over the prior year.
- Net income of $146.9 million for the first quarter, representing growth of 95% over the prior year.
- Adjusted EBITDA margins reached a record 77%.
Headline financials
Revenue & EPS history
Maravai · Revenue · Quarterly
$244M
Revenue by segment
Maravai · $244M total across 2 segments · Q1 2022
- TriLink$224M+80.5%91.5%
- Cygnus$20.6M+17.0%8.5%
Forward guidance
Maravai LifeSciences has updated its financial guidance for the full year 2022, projecting total revenue in the range of $920.0 million to $960.0 million, reflecting overall growth of 15% to 20%. Adjusted EBITDA is now expected to be in the range of $650.0 million to $690.0 million, and adjusted fully diluted EPS is expected to be in the range of $1.74 - $1.90 per share.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2022
-0.2%
Avg return
Earnings day
+2.1%
Avg return
5 days after
+1.1%
Avg return
30 days after
42%
10 / 24 earnings
Positive
+58.9%
Q4 2023
Best reaction
-36.7%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +23.4% | +10.9% | +27.5% | |
| Q4 2025 | +9.9% | +13.2% | -12.3% | |
| Q3 2025 | -0.7% | +12.5% | +28.0% | |
| Q1 2025 | -2.4% | -0.9% | +6.6% | |
| Q4 2024 | -6.4% | -13.2% | -31.4% | |
| Q3 2024 | -36.7% | -29.0% | -37.1% | |
| Q2 2024 | -6.7% | -4.3% | -0.4% | |
| Q1 2024 | +10.0% | +17.5% | -3.9% | |
| Q4 2023 | +58.9% | +57.0% | +66.5% | |
| Q3 2023 | -31.3% | -25.0% | -24.3% | |
| Q2 2023 | -3.5% | -10.1% | -5.7% | |
| Q1 2023 | -16.4% | +2.5% | -3.3% | |
| Q4 2022 | +6.9% | +3.2% | -2.4% | |
| Q3 2022 | -11.7% | -13.8% | -15.3% | |
| Q2 2022 | +2.2% | -3.5% | -20.7% | |
| Q1 2022 | +6.1% | -2.9% | +6.7% | |
| Q4 2019 | +1.4% | +1.1% | -9.7% | |
| Q4 2021 | -1.6% | +14.8% | +7.0% | |
| Q3 2020 | -1.7% | -0.4% | +6.3% | |
| Q3 2021 | +1.6% | +3.1% | +10.1% | |
| Q2 2021 | -5.7% | +8.8% | +0.6% | |
| Q1 2020 | +4.0% | +8.6% | +26.5% | |
| Q1 2021 | -4.8% | +2.1% | +13.1% | |
| Q4 2020 | -0.4% | -2.4% | -6.3% | |
| Q2 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro